Corporate integrity agreement

Whistleblower Law Collaborative LLC Wins Law360 Health Care Group of the Year

Retrieved on: 
Wednesday, March 1, 2023
Comment, Pharmacy, Health, Corporation, Corporate integrity agreement, Medicaid, Commonwealth, False Claims Act, CIA, Physician, United States v. Arthrex, Inc., AKS, Cardinal Health, OPKO Health, WLC, Medicare, Government, Anti-Kickback Statute, Mallinckrodt, Fraud, Operation Cleanslate, Adrenocorticotropic hormone (medication), Pharmaceutical industry

BOSTON, March 1, 2023 /PRNewswire/ -- Whistleblower Law Collaborative is pleased to announce it has been named a Law360 Health Care Group of the Year for 2022 .

Key Points: 
  • BOSTON, March 1, 2023 /PRNewswire/ -- Whistleblower Law Collaborative is pleased to announce it has been named a Law360 Health Care Group of the Year for 2022 .
  • Whistleblower Law Collaborative was chosen because the firm "successfully steered a host of high-stakes whistleblower suits in the health care field last year," said Law360.
  • Indeed, the award caps off an exceptional period of success for Whistleblower Law Collaborative.
  • Whistleblower Law Collaborative LLC , based in Boston, devotes its practice entirely to representing clients nationwide in bringing actions under the federal and state False Claims Acts and other whistleblower programs .

AmerisourceBergen Announces Secondary Public Offering of Common Shares and Common Share Repurchase

Retrieved on: 
Monday, November 7, 2022
General Health, Finance, Health, Professional Services, Pharmaceutical, Alliance Healthcare, Acquisition, AmerisourceBergen, Pharmacy, Substance-related disorder, U.S. Securities and Exchange Commission, Risk, Industry, Growth, Compliance, SEC, Company, Uncertainty, Form, Bankruptcy, Share repurchase, NYSE, Government, Information, Securities Exchange Act of 1934, Pressure, Securities Act of 1933, Corporation, Economics, Varick Street, Prospectus, Medicare, Medicaid, Health, Morgan Stanley, Form S-3, Failure, Pandemic, Hospital, 2nd Floor (Nina song), EDGAR, Efficiency, Solution, Marketing, ABC, State government, Corporate integrity agreement, Sale, Security (finance), Pharmaceutical industry, COVID-19

AmerisourceBergen Corporation (NYSE: ABC) (the Company) announced today a secondary public offering of 10 million shares of common stock of the Company held by Walgreens Boots Alliance Holdings LLC (the Selling Stockholder).

Key Points: 
  • AmerisourceBergen Corporation (NYSE: ABC) (the Company) announced today a secondary public offering of 10 million shares of common stock of the Company held by Walgreens Boots Alliance Holdings LLC (the Selling Stockholder).
  • The Company will not receive any proceeds from the sale of the Companys common stock by the Selling Stockholder in the offering.
  • The concurrent share repurchase will be made under the Companys share repurchase program and the repurchased shares will be held in treasury.
  • The closing of the concurrent share repurchase will be conditioned upon the closing of the offering and therefore there can be no assurance that the concurrent share repurchase will be completed.

AmerisourceBergen to Expand Global Biopharma Services Platform With Acquisition of PharmaLex

Retrieved on: 
Monday, September 12, 2022
Professional Services, Health, Other Health, Finance, General Health, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, Risk, Health, Safety, Corporation, GxP, Efficiency, Medicare, Corporate integrity agreement, NYSE, GAAP, Sale, Substance-related disorder, Securities Act of 1933, Bankruptcy, Company, Acquisition, Compliance, Growth, Pressure, Economics, LIFO, Pharmacy, Industry, Pandemic, Government, Medicaid, Sidley Austin, Solution, Uncertainty, Leadership, ABC, EPS, State government, Information, Hospital, Marketing, Lung compliance, Failure, Lists of disasters, Fine chemical, Bank, Risk management, COVID-19, AmerisourceBergen

The strategic acquisition of PharmaLex will expand our global platform of biopharma services, further advancing the strategy we detailed at our recent Investor Day, said Steven H. Collis, Chairman, President & Chief Executive Officer.

Key Points: 
  • The strategic acquisition of PharmaLex will expand our global platform of biopharma services, further advancing the strategy we detailed at our recent Investor Day, said Steven H. Collis, Chairman, President & Chief Executive Officer.
  • We look forward to welcoming the PharmaLex team to create healthier futures with AmerisourceBergen.
  • PharmaLex is a global team of scientific, regulatory, and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a products lifecycle.
  • The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations.

Givex Promotes Longtime Employee Juan Tovar to SVP of Corporate Integrations

Retrieved on: 
Tuesday, August 23, 2022
Longevity, CEO, Technology, Sale, Kalex, SVP, TSX, Multimedia, News, Corporate integrity agreement, Acquisition, Growth, Sales, Management, Online shopping

Tovar has played a key role in the global fintech company's three recent acquisitions in six months, and will manage all post-purchase integrations in his new position

Key Points: 
  • Tovar has played a key role in the global fintech company's three recent acquisitions in six months, and will manage all post-purchase integrations in his new position
    TORONTO, Aug. 23, 2022 /PRNewswire/ - Global fintech company Givex announced today the promotion of longtime employee Juan Tovar to SVP of Corporate Integrations.
  • After joining Givex in 2010 as Director of Client Services, Tovar was promoted in 2015 to Vice President of Client Services.
  • In his new role as SVP of Corporate Integrations, Tovar will continue to play a key role in Givex's acquisition growth strategy.
  • "Givex has made major strides in our strategic growth plan with the acquisitions of Counter Solutions, Loyalty Lane and Kalex in the last six months," said Don Gray, CEO of Givex.

Lieff Cabraser Announces $70.7 Million Settlement of Qui Tam Misuse of Government Funds Litigation with Gold Coast Health Plan and Certain California Medical Providers

Retrieved on: 
Friday, August 19, 2022
Health, Professional Services, Legal, Managed Care, Health Insurance, Dignity, Accusative case, Office of Inspector General, U.S. Department of Health and Human Services, Ventura County Medical Center, Dignity Health, Corporation, Human services, False Claims Act, Government, Documentation, LLP, Time, Dnata, United States Department of Justice, Achievement, Affordable Care Act, Courage, Gold, Justice, Corporate integrity agreement, Medi-Cal, Care Act 2014, Adult, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2015, Patient, Health insurance, Pharmaceutical industry

Under medical loss ratio rules, Gold Coast was required to return to the government a certain percentage of monies that it did not ultimately use on health care for this Adult Expansion population.

Key Points: 
  • Under medical loss ratio rules, Gold Coast was required to return to the government a certain percentage of monies that it did not ultimately use on health care for this Adult Expansion population.
  • This mechanism allowed the government to adequately fund care for this newly-insured population knowing that any excess amounts would be returned.
  • As a result of settlements negotiated with Gold Coast and the favored providers, Gold Coast will pay $17.2 million to the United States and the State of California.
  • The settlement was first made public by the United States Department of Justice and the California Attorney General on August 18, 2022.

Mallinckrodt plc Provides Update on Executive Committee

Retrieved on: 
Wednesday, August 17, 2022
U.S. Securities and Exchange Commission, Corporate integrity agreement, Quality, Social, National Executive Committee of the Labour Party, Science, Government Affairs Institute, Analgesic, Autoimmunity, SVP, Board on Science, Technology, and Economic Policy, SEC, Private Securities Litigation Reform Act, Ajman Specialty General Hospital, Leadership, Growth, Director, Board, Annual report, ESG, The Company, Chapter 11, Title 11, United States Code, Patient, General manager, Executive Committee, Company, EVP, Hikma Pharmaceuticals, Corporation, Program, Neurology, Corporate development, VP, Operation, Risk, Nephrology, Immunotherapy, Technology, Business operations, Commercial, Rheumatology, Ophthalmology, Biophysical environment, Patient advocacy, Management, Medicine, Mallinckrodt

DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee.

Key Points: 
  • DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee.
  • "Mallinckrodt is at an important inflection point, and the leaders of our go-forward Executive Committee will join me in guiding the business and further strengthening our focus on the patients we serve," said Mr. Olafsson.
  • For full biographies of each member of the Executive Committee, please visit https://www.mallinckrodt.com/about/executive-committee/ .
  • Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.

AmerisourceBergen Presents Long-term Vision and Guidance at Investor Day

Retrieved on: 
Wednesday, June 1, 2022
Professional Services, Health, Managed Care, Finance, General Health, Pharmaceutical, Banking, Company, ESG, Failure, Sale, NYSE, Alliance Healthcare, Efficiency, ABC, Uncertainty, Sustainability, Marketing, Share repurchase, Income, EVP, Contribution, Lists of disasters, Solution, Alliance, Health, Securities Exchange Act of 1934, Securities Act of 1933, Industry, LIFO, EPS, Corporation, Government, Risk, Information, Patient, Hospital, Economics, Acquisition, Compliance, AmerisourceBergen, Culture, Substance-related disorder, Leadership, Corporate integrity agreement, Pharmacy, SECURE Act of 2019, Pressure, SVP, Medicare, Nature, State government, Bankruptcy, Investment, Growth, GAAP, Pandemic, Medicaid, Management, Fine chemical, Renewable energy, Pharmaceutical industry, Risk management, Bank, Insurance, COVID-19

AmerisourceBergen Corporation (NYSE: ABC) today hosted an investor day event in New York City.

Key Points: 
  • AmerisourceBergen Corporation (NYSE: ABC) today hosted an investor day event in New York City.
  • The Companys fiscal year 2022 guidance does not include any potential benefit from the $1 billion share repurchase authorization.
  • AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products.
  • AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue.

AmerisourceBergen Investor Day to Highlight Strategic Imperatives and Provide Long-Term Financial Outlook

Retrieved on: 
Wednesday, June 1, 2022
Professional Services, Health, Finance, Managed Care, General Health, Pharmaceutical, Substance-related disorder, Leadership, Corporate integrity agreement, Company, Pharmacy, Board of directors, Marketing, LIFO, Securities Exchange Act of 1934, ESG, Securities Act of 1933, Share repurchase, Pressure, Corporation, Medicare, Webcast, Lists of disasters, State government, Government, Failure, Bankruptcy, Solution, Investment, Sale, Risk, Growth, Information, Hospital, Alliance, Economics, Health, NYSE, GAAP, Compliance, Pandemic, Acquisition, Alliance Healthcare, Industry, AmerisourceBergen, Culture, Board, Efficiency, Medicaid, ABC, Uncertainty, Management, Risk management, Bank, COVID-19

The investor day will include presentations by company leaders focusing on AmerisourceBergens purpose, strategic imperatives, ESG commitments, and long-term financial growth outlook.

Key Points: 
  • The investor day will include presentations by company leaders focusing on AmerisourceBergens purpose, strategic imperatives, ESG commitments, and long-term financial growth outlook.
  • The investor day live event webcast will begin at 9:00 am ET on June 1, 2022.
  • The non-GAAP financial measures should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP.
  • The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the Companys operating performance, to perform financial planning, and to determine incentive compensation.

Mallinckrodt Agrees to Pay $234 Million to Settle False Claims Act Case Brought by Whistleblower Law Collaborative Client for Unpaid Acthar Medicaid Rebates

Retrieved on: 
Tuesday, March 8, 2022
Linda, Medicaid, Epinephrine autoinjector, Centers for Medicare & Medicaid Services, CMS, Human, False Claims Act, Mylan, AMP, New Hampshire Department of Justice, Government, Corporation, Justice, Bankruptcy, Medicare, Corporate integrity agreement, FDA, State attorney general, Medicaid Drug Rebate Program, Attorney General's Office (United Kingdom), Control, Whistleblower, State, District, Center, Department, Pharmaceutical industry, Health insurance, Mallinckrodt, Adrenocorticotropic hormone (medication)

Because of Mallinckrodt's bankruptcy, federal and state governments were not able to recoup the full amount of the unpaid rebates.

Key Points: 
  • Because of Mallinckrodt's bankruptcy, federal and state governments were not able to recoup the full amount of the unpaid rebates.
  • But individuals have a voice and the power to do something about wrongdoing, thanks to whistleblower laws like the False Claims Act."
  • This is the second major success for the Whistleblower Law Collaborative in a Medicaid rebate fraud case.
  • In 2017, Mylan paid $465 million for misclassifying EpiPen as a generic drug to avoid paying the higher rebates owed on brand name drugs.

Western Announces Addition of Integral and G8 to Investor Relations Team

Retrieved on: 
Wednesday, February 9, 2022
Mining, Minerals, Natural Resources, Policy, News, Industry, Silver, SEDAR, Integral, TSX Venture Exchange, Awareness, No, Time, NI, Terminology, Intention, Company, Marketing, Achievement, Corporate integrity agreement, Uncertainty, SEC, The Exchange, Tax, Regional Municipality of Waterloo, Gold, History, Aura, Nature, Mining, Lease, G8

Western Exploration Inc. (TSX-V: WEX) (the "Company" or "Western Exploration") is pleased to announce the addition of Integral Wealth Securities Limited ("Integral") and G8 Strategies LLC ("G8") to the Company's investor relations team, for the purpose of providing certain market-making and investor relations services in accordance with the policies of the TSX Venture Exchange (the "Exchange").

Key Points: 
  • Western Exploration Inc. (TSX-V: WEX) (the "Company" or "Western Exploration") is pleased to announce the addition of Integral Wealth Securities Limited ("Integral") and G8 Strategies LLC ("G8") to the Company's investor relations team, for the purpose of providing certain market-making and investor relations services in accordance with the policies of the TSX Venture Exchange (the "Exchange").
  • In addition, the Company has also entered into a services agreement with G8, pursuant to which, among other things, G8 has agreed to provide certain investor relations services in accordance with Policy 3.4 of the Exchange (the "G8 Agreement").
  • G8 is a US based firm located in Reno, Nevada, that specializes in providing multinational companies with investor relations, communications and marketing services.
  • Neither the Integral Agreement nor the G8 Agreement contain any performance factors, and neither Integral nor G8 will receive any common shares or options as compensation.